Prof. Dr. med. et phil. nat. Markus Jörger
chief of service
Medizinische Onkologie und Hämatologie · Dept. I
AMG 355 20220028
Oct 17, 2024Eine Phase-1-Studie am Menschen zur Bewertung der Sicherheit, Verträglichkeit, Pharmakokinetik und Wirksamkeit von AMG 355 als Monotherapie und in Kombination mit Pembrolizumab bei Patienten mit fortgeschrittenen soliden Tumoren
Clinical Studies - Oct 17, 2024 - Dec 31, 2028
Ongoing
Project leader: Jörger Markus
Members: Donno Monica, Müller Fiona
SAKK 66/22 - Invincible 4 SAKK
Oct 17, 2024Protocol SAKK 66/22: Intratumoral INT230-6 followed by neoadjuvant immunochemotherapy in patients with early triple-negative breast cancer (TNBC). An openlabel randomized two-cohort phase 2 clinical trial. INVINCIBLE-4-SAKK
Clinical Studies - Oct 17, 2024 - Dec 31, 2029
Ongoing
Project leader: Jörger Markus
Members: Dei Cas Alissa, Müller Fiona
A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors
Aug 27, 2024
Clinical Studies - Aug 27, 2024 - Dec 31, 2099
Ongoing
Project leader: Jörger Markus
Members: Bürki Ramona, Quinter Janine
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08) (Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)
Aug 13, 2024
Clinical Studies - Aug 13, 2024 - Dec 31, 2099
Ongoing
Project leader: Jörger Markus
Members: Harder Anja, Quinter Janine
A first-in-human, open-label, multicenter Phase l/ll study to evaluate the safety and anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1)
Jun 13, 2024
Clinical Studies - Jun 13, 2024 - Dec 31, 2028
Ongoing
Project leader: Jörger Markus
Members: Sennhauser Andrina, Müller Fiona
A single-arm phase II trial of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer.
Dec 21, 2023
Clinical Studies - Dec 21, 2023 - Dec 31, 2027
Ongoing
Project leader: Jörger Markus
Members: Quinter Janine, Kehl Jeanine
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Oct 30, 2023
Clinical Studies - Oct 30, 2023 - Dec 31, 2099
Ongoing
Project leader: Jörger Markus
Members: Bürki Ramona, Quinter Janine
A Phase 1/2 Study of BMS-986408 Alone and in Combination with Nivolumab or with Nivolumab and Ipilimumab in Participants with Advanced Solid Tumors
Jun 21, 2023Das primäre Ziel dieser Studie ist die Charakterisierung des Sicherheitsprofils von BMS-986408 als Monotherapie und in Kombination mit Nivolumab oder Nivolumab und Ipilimumab, um die maximal verträgliche Dosis (MTD) zu ermitteln. Außerdem soll die em...
Clinical Studies - Jun 21, 2023 - Dec 31, 2030
Ongoing
Project leader: Jörger Markus
Members: Hutter Franziska
BMS CA099-003
Jun 21, 2023A Phase 1/2 Study of BMS-986408 Alone and in Combination with Nivolumab or with Nivolumab and Ipilimumab in Participants with Advanced Solid Tumors
Clinical Studies - Jun 21, 2023 - Dec 31, 2099
Ongoing
Project leader: Jörger Markus
Members: Hutter Franziska, Müller Fiona
A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Mono-therapy and in Com-bination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours (TROPION-PanTumor03)
Mar 2, 2023
Clinical Studies - Mar 2, 2023 - Oct 2, 2023
Completed
Project leader: Jörger Markus
Members: Bürki Ramona, Quinter Janine
A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors
Jan 11, 2023Die Studie untersucht die Sicherheit, Verträglichkeit, Pharmakokinetik und Wirkung von MK-0472 alleine und kombiniert mit Pembrolizumab. «Pharmakokinetik» bedeutet unter anderem die Aufnahme, Verarbeitung und Abbau der Substanz im Körper. Es werden v...
Clinical Studies - Jan 11, 2023 - Dec 31, 2099
Ongoing
Project leader: Jörger Markus
Members: Donno Monica, Quinter Janine
IP-001_RFA (IP-IIO-622): Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter Phase 1b/2a trial in colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma patients
Nov 8, 2022Diese Studie untersucht die Sicherheit und erste Wirksamkeit einer immunstimulierenden thermischen Ablation in Kombination mit dem Prüfpräparat IP-001, welches nach der Ablation in den Tumor injiziert wird (intratumoral). Die thermische Ablation ist...
Clinical Studies - Nov 8, 2022 - Dec 31, 2099
Ongoing
Project leader: Jörger Markus
Members: Wittwer Yvonne, Quinter Janine
CATALYM CTL-002-001 A PHASE 1/2, FIRST-IN-HUMAN, TWO-PART, OPEN-LABEL CLINICAL TRIAL OF INTRAVENOUS ADMINISTRATION OF CTL-002 GIVEN AS MONOTHERAPY AND/OR IN COMBINATION WITH AN ANTI-PD-1 CHECKPOINT INHIBITOR IN SUBJECTS WITH ADVANCED-STAGE, RELAPSED/REFRACTORY SOLID TUMORS
Sep 2, 2022Diese klinische Studie wird durchgeführt, um ein neues Prüfpräparat mit der Bezeichnung "CTL-002" zu testen. CTL-002 gehört zu einer Klasse von Medikamenten, die als monoklonale Antikörper bezeichnet werden. Antikörper sind vom Immunsystem hergestell...
Clinical Studies - Sep 2, 2022 - Dec 31, 2099
Ongoing
Project leader: Jörger Markus
Members: Bürki Ramona, Quinter Janine
ANV419 Single Agent (Parts A-C) or Combination (Part D) First in Human Study Phase 1/2: Open-label, Dose Escalation and Expansion Study in Patients with Relapsed/Refractory Advanced Solid Tumors and Multiple Myeloma. (Anaveon)
Mar 3, 2022Diese klinische Studie wird durchgeführt, um ein neues Arzneimittel mit dem Namen ANV419 zu testen. Dieses neue Arzneimittel hat im menschlichen Körper eine Wirkung ähnlich Interleukin-2. Diese klinische Studie wird durchgeführt, um die Sicherheit...
Clinical Studies - Mar 3, 2022 - Mar 2, 2024
Completed
Project leader: Jörger Markus
Members: Wittwer Yvonne, Quinter Janine
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
Jan 13, 2022MK-1084 enthält einen chemischen Wirkstoff und hemmt gezielt das mutierte KRAS-G12C-Protein. Generell spielen RAS-Proteine in der Zellteilung und Zelldifferenzierung eine grosse Rolle und wenn diese Proteine zu stark aktiviert sind, kann das zu Krebs...
Clinical Studies - Jan 13, 2022 - Dec 31, 2099
Ongoing
Project leader: Jörger Markus
Members: Donno Monica, Quinter Janine
DS1062-A-U303 ( TROPION-lung07) A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations TROPION-Lung07
Oct 8, 2021
Clinical Studies - Oct 8, 2021 - Dec 31, 2099
Ongoing
Project leader: Jörger Markus
Members: Harder Anja, Quinter Janine
A multicenter, non-randomized, open-label phase 1b study to determine the maximum tolerated and recommended phase 2 dose of the ATR Inhibitor BAY 1895344 in combination with pembrolizumab and characterize its safety, tolerability, pharmacokinetics and preliminiary anti-tumor activity in patients with advanced solid tumors
Apr 14, 2021BAY-1895344 und Pembrolizumab bei ausgewählten Tumoren mit genetischen Alterationen von ATM.
Clinical Studies - Apr 14, 2021 - Feb 21, 2022
Automatically Closed
Project leader: Jörger Markus
ON-TRK: PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib
Apr 14, 2021TRK fusion cancer is rare but presents as a variety of solid tumors. Larotrectinib is a highly selective TRK inhibitor that, in a pooled analysis of patients in phase 1/2 clinical trials, demonstrated an effective and sustained response in the ma...
Clinical Studies - Apr 14, 2021 - Dec 31, 2099
Ongoing
Project leader: Jörger Markus
Members: Kern Julia, Quinter Janine
SAKK 17/18 Origin
Mar 8, 2021A significant number of patients with malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) are not cured with available treatments and will eventually relapse. After relapse treatment options are limited. Preclinical in vitro s...
Clinical Studies - Mar 8, 2021 - Sep 26, 2024
Completed
Project leader: Jörger Markus
Members: Scherrer Julia, Quinter Janine
Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter phase Ib/IIa trial with expansion cohorts in melanoma and soft tissue sarcoma patients
Oct 7, 2020Diese Studie untersucht die Sicherheit und erste Wirksamkeit einer immunstimulierenden intratumoralen Laser-Wärmetherapie in Kombination mit dem Studienmedikament IP-001, welches in den Tumor injiziert wird. Alle Patienten in dieser Studie erhalten d...
Clinical Studies - Oct 7, 2020 - Dec 31, 2099
Ongoing
Project leader: Jörger Markus
Members: Wittwer Yvonne, Quinter Janine